Anna Purdum

405 total citations
22 papers, 316 citations indexed

About

Anna Purdum is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Anna Purdum has authored 22 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Pathology and Forensic Medicine and 7 papers in Genetics. Recurrent topics in Anna Purdum's work include CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Anna Purdum is often cited by papers focused on CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Anna Purdum collaborates with scholars based in United States and United Kingdom. Anna Purdum's co-authors include Vincent Lin, Sean D. Sullivan, Aasthaa Bansal, Scott D. Ramsey, Lynn Navale, Paul Cheng, Joshua A. Roth, Michael S. Broder, Sheila R. Reddy and Jun Kawashima and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Oncologist.

In The Last Decade

Anna Purdum

21 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Purdum United States 8 262 105 59 53 48 22 316
Zahra Mahmoudjafari United States 10 304 1.2× 31 0.3× 39 0.7× 56 1.1× 126 2.6× 75 449
Razan Mohty United States 10 149 0.6× 41 0.4× 21 0.4× 47 0.9× 52 1.1× 43 257
Kirsten M Boughan United States 7 146 0.6× 33 0.3× 16 0.3× 64 1.2× 54 1.1× 35 263
Clint Divine United States 8 180 0.7× 20 0.2× 28 0.5× 15 0.3× 39 0.8× 16 259
Lamis Eldjerou United States 10 178 0.7× 23 0.2× 25 0.4× 55 1.0× 29 0.6× 22 260
David M. Cordas dos Santos Germany 8 251 1.0× 25 0.2× 32 0.5× 45 0.8× 82 1.7× 16 304
Marta García‐Recio Spain 6 245 0.9× 28 0.3× 59 1.0× 39 0.7× 46 1.0× 12 294
Tejaswini Dhawale United States 9 164 0.6× 24 0.2× 18 0.3× 32 0.6× 20 0.4× 21 218
Forat Lutfi United States 10 194 0.7× 17 0.2× 34 0.6× 54 1.0× 39 0.8× 49 257
Emma Grigor Canada 7 143 0.5× 11 0.1× 23 0.4× 37 0.7× 35 0.7× 21 265

Countries citing papers authored by Anna Purdum

Since Specialization
Citations

This map shows the geographic impact of Anna Purdum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Purdum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Purdum more than expected).

Fields of papers citing papers by Anna Purdum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Purdum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Purdum. The network helps show where Anna Purdum may publish in the future.

Co-authorship network of co-authors of Anna Purdum

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Purdum. A scholar is included among the top collaborators of Anna Purdum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Purdum. Anna Purdum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Kahl, Brad S., et al.. (2020). Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review. Blood. 136(Supplement 1). 42–43. 2 indexed citations
4.
5.
6.
Klink, Andrew J., Chadi Nabhan, Choo Hyung Lee, et al.. (2020). Real-World Management and Outcomes of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in the United States. 6(1). 7 indexed citations
7.
Kilgore, Karl M., et al.. (2020). Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A Real-World Look at Patient Characteristics, Healthcare Utilization and Costs. Biology of Blood and Marrow Transplantation. 26(3). S43–S44. 3 indexed citations
8.
Pasquini, Marcelo C., Frederick L. Locke, Alex F. Herrera, et al.. (2019). Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood. 134(Supplement_1). 764–764. 72 indexed citations
9.
10.
Bansal, Aasthaa, Sean D. Sullivan, Vincent Lin, et al.. (2019). Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models. Medical Decision Making. 39(3). 294–298. 19 indexed citations
11.
Purdum, Anna, et al.. (2019). Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. The Oncologist. 24(9). 1229–1236. 25 indexed citations
12.
13.
Lin, Vincent, et al.. (2018). Systematic literature review of health-related quality of life among aggressive non-Hodgkin lymphoma survivors. Current Medical Research and Opinion. 34(8). 1529–1535. 8 indexed citations
14.
15.
Roth, Joshua A., Sean D. Sullivan, Vincent Lin, et al.. (2018). Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. Journal of Medical Economics. 21(12). 1238–1245. 94 indexed citations
16.
Bansal, Aasthaa, Vincent Lin, Sean D. Sullivan, et al.. (2018). Estimating Long-Term Survival for Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy: A Comparison of Standard and Mixture Cure Models. Biology of Blood and Marrow Transplantation. 24(3). S310–S310. 2 indexed citations
17.
Purdum, Anna, et al.. (2017). Total 1-year cost of diffuse large B-cell lymphoma (DLBCL) beyond first line (1L) therapy: A retrospective cohort analysis.. Journal of Clinical Oncology. 35(15_suppl). e18333–e18333. 1 indexed citations
18.
Shankaran, Veena, Jesse D. Ortendahl, Anna Purdum, et al.. (2015). Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. American Journal of Clinical Oncology. 41(1). 65–72. 26 indexed citations
19.
Ortendahl, Jesse D., et al.. (2014). Cost-Effectiveness of Cetuximab as First-Line Treatment for Metastatic Colorectal Cancer in the United States. Value in Health. 17(3). A86–A86. 4 indexed citations
20.
Purdum, Anna, Kathleen A. Johnson, & Denise Globe. (2004). Comparing total health care costs and treatment patterns of HIV patients in a managed care setting. AIDS Care. 16(6). 767–780. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zahra Mahmoudjafari Breakdown of academic impact, for papers by Razan Mohty Breakdown of academic impact, for papers by Kirsten M Boughan Breakdown of academic impact, for papers by Clint Divine Breakdown of academic impact, for papers by Lamis Eldjerou Breakdown of academic impact, for papers by David M. Cordas dos Santos Breakdown of academic impact, for papers by Marta García‐Recio Breakdown of academic impact, for papers by Tejaswini Dhawale Breakdown of academic impact, for papers by Forat Lutfi Breakdown of academic impact, for papers by Emma Grigor
Rankless by CCL
2026